chronic lymphocytic lymphoma/small lymphocytic lymphoma (CLL/SLL)

June 25, 2019

Zanubrutinib-Gazyva Shows Promise for CLL/SLL, Follicular Lymphoma

News

Zanubrutinib in combination with Gazyva (obinutuzumab) leads to clinically meaningful responses and is well-tolerated by patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) and follicular lymphoma, a Phase 1b trial ... Read more

May 17, 2019

FDA Approves Venclexta-Gazyva Combo for Untreated CLL/SLL Patients

News

The U.S. Food and Drug Administration (FDA) has approved the double combination therapy of Venclexta (venetoclax) and Gazyva (obinutuzumab) for the treatment of adults with newly diagnosed chronic lymphocytic leukemia ... Read more

January 9, 2019January 31, 2019

First-line Imbruvica-Gazyva Therapy Extends Survival Without Disease Progression in CLL/SLL Patients, Phase 3 Study Shows

News

First-line treatment with Imbruvica (ibrutinib) plus Gazyva (obinutuzumab) significantly extends the time patients with chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL) live without cancer progression, and it also increases their ... Read more

November 5, 2018

Imbruvica Combo Improves Long-term Survival in CLL/SLL Patients, Updated Phase 3 Results Show

News

Combining AbbVie’s Imbruvica (ibrutinib) with Treanda (bendamustine) and Rituxan (rituximab) improves long-term survival outcomes in patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) whose cancer reappeared or ... Read more

November 3, 2016

Cellectar Reveals Phase 2 Study Design for Investigational Therapy in Lymphoma, Myeloma Patients

News

Cellectar Biosciences has revealed the study design of an upcoming Phase 2 trial examining the investigational compound CLR 131 in multiple myeloma and a number of lymphoma subtypes. The study, which ... Read more